UK Prostate Cancer Consultants

Professor Robert Huddart is a Consultant Clinical Oncologist based at The Royal Marsden Hospital.

Prof Huddart joined The Royal Marsden as a Registrar in 1989 and was appointed Senior Lecturer and Honorary Consultant in Clinical Oncology at The Royal Marsden and The Institute of Cancer Research in 1995.

Prof Huddart is a Reader in Urological Oncology (since 2007) at the Institute of Cancer Research (ICR), leading a team in the Division of Radiotherapy and Imaging that researches bladder and testicular cancer. He is one of the ICR’s top scientists in the Everyman laboratories and also an Honorary Consultant in Urological Oncology at The Royal Marsden, where he manages and treats patients with urological cancer - cancer that affects the kidney, bladder, prostate, testicles and penis.

He completed a Master of Arts and a Bachelor of Medicine at Oxford, and a Bachelor of Surgery at the University of London before undertaking general medical training in Oxford and Cambridge. He gained membership to the Royal College of Physicians and then moved to The Royal Marsden for specialist training in oncology. Dr Huddart was awarded gold medals in both stages of the examination to become a Fellow of the Royal College of Radiologists. He first joined the ICR to complete a PhD in the molecular biology of testicular cancer with Professor Colin Cooper.

“Working as a clinical academic at the ICR and The Royal Marsden provides an almost unique opportunity in the UK of working and researching at the cutting edge of oncology, meeting and working with some of the UK's top cancer scientists and being able to investigate and use new technologies and developments. This, combined with the excellence of cancer care within The Royal Marsden, means there is no better place, in my view, for an oncologist to be,” says Prof Huddart.

He recently retired (after 6 years) as Chair of the National Cancer Research Institute (NCRI) testicular cancer group, and jointly leads the ICR’s postgraduate course in oncology. Most recently, he has qualified for a Postgraduate Certificate in Education from University College, London. In the future, Dr Huddart hopes to be involved in “developing new personalised treatments which make a real impact on the outlook of the patients we see each week”. He continues to contribute nationally through the Royal College of Radiologists (currently sitting on Specialist Training Board and quality assurance subcommittee) and regionally as a member of the London School of Oncology Board and Training Program director.

Prof Huddart is a member of the following national groups: NCRI Testis Cancer Group, including survivorship sub-group; NCRI Bladder Cancer group, including its localised and advanced sub-groups; CT Rad workstream 3; NCIN urology site-specific reference group; NICE clinical guideline development group for bladder cancer.

Dr Richard Shaffer is a Consultant Clinical Oncologist based at Royal Surrey County Hospital NHS Foundation Trust.

Dr Shaffer specialises in using chemotherapy and radiotherapy to treat brain tumours, prostate and bladder cancer, and skin cancer. He has extensive experience of using highly-technical radiotherapy, including Intensity Modulated Radiation Therapy (IMRT) for prostate cancer and brain tumours. He is able to offer IGRT (image-guided radiotherapy) for prostate cancer. He is currently developing a local intracranial stereotactic radiotherapy service.

He has an interest in the treatment of benign disease with radiotherapy, including early Dupuytren's disease of the hand, Ledderhose disease of the foot, and plantar fasciitis with radiotherapy. To this end he helped write the RCR guidelines on this topic, and acts as a medical advisor to the British Dupuytrens Society.

He is currently the chair of the Technical Radiotherapy Group, chairs the Network Brain Tumour Working Group, and is an active member of the St Lukes Radiotherapy Strategy Group. He is a member of the NCRI Brain Tumour Clinical Studies Group. He is also a trustee of the Fountain Centre, a charity which provides information, support, counselling and complementary therapies for cancer patients and their carers and relatives at St Lukes Cancer Centre.

Previous to his role at the Royal Surrey County Hospital, Dr Shaffer completed a Clinical Fellowship in Radiation Oncology at the British Columbia Cancer Agency in Vancouver, Canada. He gained further skills in specialist registrar posts at Charing Cross Hospital, Royal Free Hospital and University College London Hospital.

Dr Prabir Chakraborti is a Consultant Clinical Oncologist based at The Derby Teaching Hospitals NHS Foundation Trust.

Dr Chakraborti has a special interest in Urology, Lung, GI tumours and breast sarcoma In the Derby and Nottingham area.  He is a member of the Fellow of Royal College of Surgeons, Fellow of Royal College of Radiologists (Oncology) and the Medical Defence Union

Dr Chakraborti has been involved in the management and treatment of cancer patients since 1990. He trained in various prestigious and teaching hospitals in London, including the Royal London Hospital, St Bartholomew’s Hospital, Charing Cross Hospital and Mt Vernon Hospital. An established oncologist of long duration, the provision of treatment maintaining the highest quality and offering state of the art technology together with an up-to-date knowledge base, remain Mr Chakraborti’s top priorities.  Mr Chakraborti is an active and prolific participant in a number of national and international trials of breast and urology patients.

Dr Paula Wells is a Consultant Clinical Oncologist based at Barts NHS Trust.

Dr Wells' oncology training was undertaken at St. Bartholomew’s, UCLH and Mount Vernon Hospitals.  Following her Fellowship, she undertook a postgraduate research degree at Imperial College School of Medicine, Hammersmith Hospital. There she investigated the potential for Positron Emission Tomography (PET) to demonstrate the biological effects of chemotherapy in tissue. She has published a number of papers in this area and was awarded a PhD for her work. Subsequently she completed her post doctoral training at the Royal Marsden Hospital, principally with the Academic Urology Unit.

Dr Paula Wells specialises in the management of patients with genitourinary (bladder and prostate) and thoracic (lung and mesothelioma) malignancies. Furthermore Dr Wells has expertise in the delivery of real time dynamic prostate brachytherapy for patients with early stage, localised prostate cancer.

Dr Wells has recieved numberous awards including :

Rohan Williams Medal CLinical Oncology 1994
British Oncological Association Young Investigator Award 1996
European Society for Therapeutic Radiation Oncology Travel Award 1996
Winner of Royal College of Radiologists national competition for Glaxo Wellcome Fellowship 1996
American Society Clinical Oncology Merit Award 1997
Cancer Research Campaign Clinical Research Fellowship 2000

Dr Marcus Wise is a Consultant Clinical Oncologist based at The Rosemere Cancer Centre in Preston.

Dr Wise qualified at Manchester Medical School in 1990.  After training in general medicine and surgery he took up a registrar post in oncology at the Christie Hospital.

He has extensive experience in a wide range of tumour sites involving use of chemotherapy and radiotherapy with a special interest in lower gastrointestinal, urological (including renal carcinoma) and upper gastrointestinal.

He was appointed to a Consultant post at Royal Preston Hospital, Rosemere Cancer Centre, with peripheral clinics at Blackburn and Burnley in 2002. 

Dr Jason Lester is a Consultant Clinical Oncologist based at The Velindre Cancer Centre in Cardiff.

Dr Lester qualified from Guy's Hospital Medical School, London in 1993 and trained in general medicine in the South East of England. He completed his oncological training in 2003, and was appointed as a Consultant Oncologist at Velindre Cancer Centre the same year, where he is currently Deputy Clinical Director and Lead Clinican for lung cancer in the Trust, bringing vast experience and expertise and offering specialist cancer diagnosis and treatment.

He advises patients on all aspects of Non-surgical treatment of lung cancer, mesothelioma and urological cancers (prostate, kidney and bladder cancer); Chemotherapy and targeted therapy for lung and urological cancers; Stereotactic radiotherapy for early lung cancer; Combined modality therapy for locally advanced lung cancer; Brachytherapy for prostate cancer; IMRT / IGRT radiotherapy for prostate cancer; Bladder sparing treatment for bladder cancer. He is responsible for prescribing and supervising the administration of radiotherapy, radioisotope treatment, cytotoxic chemotherapy and hormone therapy. He is also the Clinical Lead for the All Wales Prostate Cancer Brachytherapy service based at Velindre Cancer Centre. 

Dr Lester is a member of Royal College of Physicians, Fellow of the Royal College of Radiologists, Honorary Research Fellow, Cardiff School of Medicine and British Thoracic Oncology Group Committee Member. He also manages The Stepping Stones Appeal, the Wales-based lung cancer research fund.

Dr Duncan McLaren is a Consultant Clinical Oncologist based at The Edinburgh Cancer Centre, Western General Hospital, Edinburgh.

Dr McLaren undertook Undergraduate training at St Mary's Hospital Medical School in London and also undertook an intercalated BSc in Clinical Science where he gained First Class Honours. His General Medical training was at Queens University Hospital Nottingham and he had specialist cancer training at Velindre Cancer Hospital Cardiff. He was given a clinical Fellowship specialising in GU oncology at the British Columbia Cancer Agency, Vancouver and was appointed as Consultant Clinical Oncologist and Honorary Clinical Senior Lecturer at the Edinburgh Cancer Centre in 1998. 

Dr McLaren is a specialist in Genito-Urinary Oncology and runs a large practice offering non-surgical treatment with radiotherapy and chemotherapy for Urological Cancer patients. He has a particular interest in Prostate Brachytherapy (seeds). Edinburgh was the first Scottish Centre to offer this treatment in 2001. He can offer dose-escalated radiotherapy with IMRT for prostate cancer and conformal radiotherapy for bladder cancer. Neoadjuvant chemotherapy is routinely used before surgery or radiotherapy for bladder cancer. He provides the Scottish Prostate Brachytherapy Service in conjunction with Glasgow. The Edinburgh brachytherapy team was honoured to win Hospital Doctor Oncology Team of the year in 2005

Dr McLaren is a member of the Royal College of Radiologists (London), Royal College of Physicians, British Urological Group, South East Scotland GU Cander Group (SCAN), UK and Ireland Brachytherapy Users Group and is appointed to the National Cancer Research Network Clinical Trials (NCRN) group for Prostate Cancer and Bladder Cancer

Amit Bahl is Consultant Clinical Oncologist and Clinical Director based at The Bristol Haematology & Oncology Centre.

Dr Bahl has a special interest in breast and urological cancers.

He has led and developed the prostate brachytherapy service at Bristol.  He has been an expert adviser to NICE for the technology appraisal on new drugs and an external service reviewer. He has been awarded the fellowship of the Royal College of Physicians.

Dr Bahl is a current member of the National Cancer Research Institute for prostate and bladder cancer, and has supervised several research projects. He has previously been in the NCRI Renal clinical studies group. He is an Executive Committee member of the British Uro-oncology group. Dr Bahl is actively involved in research into breast, prostate and bladder cancers, participates in clinical trials and regularly publishes articles and has several presentations at national and international meetings.

In 2012, Dr Bahl was awarded the Cochrane Shanks Jalil Professorship by the Royal College of Radiologists, London.

Dr Amir Montazeri is a Consultant Clinical Oncologist at The Clatterbridge Centre for Oncology.

Dr Montazeri studied medicine in Tehran and completed his clinical oncology training on the Wirral, UK, where he remains today.

He specialises in colorectal and urological cancers, giving treatment with both chemotherapy and radiotherapy. He also has an interest in Selective Internal Radiation Therapy.

Dr Montazeri is a member of Royal College of Physicians and Surgeons of Glasgow, a Fellow of Royal College of Radiologists and a member of British Uro-oncology Group.

Dr Alison Birtle is a Consultant Clinical Oncologist based at The Rosemere Cancer Centre, Preston.

Dr Birtle’s specialist interests cover chemotherapy for urological tumours, targeted therapy and radiotherapy developments. She trained in London at Charing Cross and Westminister Medical School and as a specialist registrar in clinical oncology in North Thames. She  completed her MD Thesis at the Institute of Urology, University College London, in PSA negative prostate cancer and finished site specialised training at the  Academic Urology Unit, Royal Marsden Hospital.

In November 2007, Dr Birtle was appointed ‘Honorary Clinical Senior Lecturer’ at The University of Manchester in recognition of her academic and clinical research of cancer.

She was Clinical Lead for Research for Lancs & South Cumbria Cancer Research Network until April 2014 and is a member of the Research and innovation Committee at Lancs Teaching Hospitals NHS Foundation Trust and an active member of the Cancer Research Partnership Group.

Dr Birtle is committee member of the British Uro-Oncology Group and Trustee of the Action on Bladder cancer.